AIML.CN AI/ML Innovations CNQ C$0.035 on 02 Feb 2026: Forecast implies -51.16% downside

AIML.CN stock trades at C$0.035 on 02 Feb 2026 after a one-year fall of 72.00%. Volume is elevated at 592,552 shares versus a 50-day average of 399,491, signaling short-term trader interest. Investors in AI/ML Innovations Inc. (AIML.CN) on the CNQ should weigh low liquidity against the company’s patent-pending health monitoring product and stretched valuation metrics before placing speculative bets.

AIML.CN stock: real-time price, volume and technicals

The stock is C$0.035 with a day range of C$0.035–C$0.035 and relative volume 1.48. RSI sits at 40.70, indicating mild downside bias. The 50-day average price is C$0.0374 and the 200-day average is C$0.0568, both above the current price which signals a short-term downtrend.

On-chain technicals show ADX 14.53 (no trend) and Bollinger middle band C$0.04. Traders should note thin absolute price moves and a high relative volatility profile given the share price level.

AIML.CN stock: fundamentals, market cap and valuation

AI/ML Innovations Inc. has market cap C$5,889,240.00 and 168,264,000 shares outstanding. Trailing EPS is -0.03 and trailing PE is -1.17, reflecting losses. Price-to-sales is 35.00 and price-to-book is 4.58, both well above healthcare sector norms and indicating a stretched valuation for minimal revenue per share.

Investors should expect thin revenue per share (0.008) and negative operating cash flow per share (-0.03). These ratios highlight that AIML.CN stock is still in an early, loss-making phase despite its AI healthcare positioning.

Meyka AI rates and AIML.CN stock forecast

Meyka AI rates AIML.CN with a score out of 100: the model gives 58.15/100, grade C+ (HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst signals. The company rating from other data sources is weaker (company rating C-, recommendation Strong Sell as of 2026-01-30).

Meyka AI’s forecast model projects a 12‑month price of C$0.01710, which vs the current C$0.035 implies an estimated -51.16% downside. Forecasts are model-based projections and not guarantees.

AIML.CN stock: earnings, cash flow and balance-sheet signals

Recent trailing twelve-month metrics show negative net income per share -0.0310 and operating cash flow per share -0.02635. The current ratio is 2.09, and debt-to-equity is low at 0.11, which gives modest short-term liquidity cover despite negative profitability.

Interest coverage is deeply negative (-41.09), which stresses operating leverage. Days sales outstanding is 575.81 days, signaling collection issues that raise working-capital risks for AIML.CN stock.

Sector context and AI strategy for AIML.CN stock

AI/ML Innovations operates in Healthcare digital services and wearable tech, a niche where clinical validation matters more than pure AI hype. The Canadian healthcare sector average PE is 14.24, and AIML.CN’s valuation metrics sit above sector norms, increasing relative risk.

The company’s patent-pending personal health monitoring system is a strategic asset. However, limited headcount and minimal revenue scale mean commercialization execution is the key risk and opportunity for AIML.CN stock.

AIML.CN stock technical outlook and price targets

Scenario targets for AIML.CN stock from a risk-first view: Bear C$0.020 (implied -42.86%), Base C$0.040 (implied +14.29%), Bull C$0.100 (implied +185.71%). Each target assumes different execution paths for commercialization and financing.

Near-term technicals favor the bear/base case until the price closes above the 50-day average C$0.0374 on sustainable volume. Watch volume and a turnaround in receivables metrics for a credible reversal.

Final Thoughts

Key takeaways on AIML.CN stock: the market price C$0.035 on 02 Feb 2026 reflects weak fundamentals with pockets of product-led upside. Valuation metrics (P/S 35.00, P/B 4.58) are high versus healthcare peers and EPS is negative (-0.03), which raises capital-risk questions. Meyka AI’s model projects C$0.01710 over 12 months, implying -51.16% versus today; this underscores downside risk if commercial traction stalls. Conversely, a validated rollout of the patent-pending monitoring system could support the base and bull scenarios outlined above. For AI-focused investors, AIML.CN stock is a high-volatility, speculative exposure to healthcare AI that needs careful monitoring of revenue recognition, receivables aging and financing events. This analysis uses Meyka AI as an AI-powered market analysis platform and should not be taken as financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.